Aqara To Unveil New Smart Home Devices at IFA 2023, Embracing the Future of Connected Living
31.8.2023 10:00:00 EEST | Business Wire | Press release
Aqara, a leading provider of smart home products, is thrilled to announce its attendance at this year’s IFA show, where it will unveil multiple new smart home devices. These include the Smart Lock U200, the Camera E1, the Dual Relay Module T2, the Ceiling Light T1M, and an EU-style wall outlet. Aqara will be showcasing these new devices along with other smart home technology and solutions at its booth (H22, 214).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831580646/en/
Aqara unveils new smart home devices at IFA 2023 (Photo: Business Wire)
With a commitment to making smart home technology more accessible to households worldwide, Aqara continues to expand its product portfolio to enable various home automation use cases. The five new products previewed at IFA are expected to become available for order in the coming months.
Smart Lock U200 - As a retrofit solution, Aqara’s new Smart Lock U200 offers the convenience of keyless home access to a broad user base. The lock operates with existing cylinders and requires no drilling or door modifications. As Aqara’s first Matter-over-Thread smart lock, the U200 will be interoperable with a wide array of smart home ecosystems and products. Using an Aqara NFC card or specified NFC-enabled mobile devices, users can unlock easier than ever before. Other secure access options include auto-unlock, fingerprints, PIN codes and mobile apps. Aqara also plans to initiate its first crowdfunding campaign on Kickstarter for the Smart Lock U200 later this year.
Camera E1 - Aqara is expanding its home surveillance camera portfolio with the 2K, Pan/Tilt Camera E1. Similar to other indoor home cameras from the Company, this new camera supports major third-party platforms like Apple Home (including HomeKit Secure Video), Amazon Alexa, and Google Home. Built upon Wi-Fi 6 and Bluetooth 5.2, the camera enables smoother live view and easier pairing experience. Other features of the E1 camera include AI-enabled person detection, person tracking and flexible storage options such as cloud storage, microSD card, and NAS storage.
Dual Relay Module T2 - The Dual Relay Module T2 is a versatile solution for home automation, allowing easy control of various devices ranging from lights, motorized window coverings, garage doors, boilers, to electric heaters and underfloor heating. Built upon Zigbee 3.0, the dual relay module features Matter-over-bridge support and is compatible with major third-party platforms. It also allows users to monitor energy consumption and ensures peace of mind with safety features like overheat protection, overload protection, and configurable power limits. Powered by AC (100-250V) or DC (24-60V), the 2-channel relay supports a total (and per-channel) loads of up to 10 Amps.
Ceiling Light T1M - Following the LED Strip T1, which was announced in August 2023, Aqara is introducing its second smart lighting device to the global market. With an approximate diameter of 50 centimeters, the Ceiling Light T1M offers a broad spectrum of hues from dimmable whites to 16 million vibrant colors, allowing users to set the atmospheric lighting for different occasions and moods. Additional features include an independently addressable RGB ring for gradient effects and integration into home automation, such as using the RGB ring as a status light to indicate potential threats like an open door or water leak. Similar to other Zigbee devices from Aqara, the Ceiling Light T1M features the low idle consumption, Matter-over-bridge support, and the wide compatibility with major platforms.
EU-style wall outlet - Finally, Aqara is introducing a smart wall socket for the EU market. This outlet allows easy control of plugged devices via mobile apps, voice assistants and home automation. It also helps users track energy consumption. Moreover, this new outlet can be configured to sense and report the status of the plugged device, making it possible to use the on/off status of an appliance as an automation trigger. For example, to close the curtains and dim the lights when the TV is turned on, or to notify the user when the washing machine finished the laundry. As a repeater of the Zigbee network, this socket outlet also enhances network reliability and responsiveness of other compatible smart home devices.
“Aqara is at the forefront of innovating the smart home experience, and these new products are a testament to our dedication. Each of them is crafted with the user's convenience and lifestyle in mind, reflecting our commitment to quality and innovation,” said Cathy You, Aqara Senior Vice President, Global Business and Strategy. “We invite everyone to join us at our booth to experience firsthand the future we're building together.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831580646/en/
Contact information
For Media Inquiries:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom